Attenuated Bordetella Strains
AssigneesInstitut Pasteur de Lille, Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsCamille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
Life of this patent
Estimating the term…
Abstract
A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
Claims8
A vaccine comprising a pharmaceutically acceptable carrier and a dose of a live attenuated Bordetella strain which is able to colonize and induce protective immunity against a microbial infection in a subject when administered to the subject.
A method of making a vaccine comprising a pharmaceutically acceptable carrier and a dose of a live attenuated Bordetella strain which is able to colonize and induce protective immunity against a microbial infection in a subject when administered to the subject, the method comprising the steps of:
- providing the live attenuated Bordetella strain, wherein the strain comprises at least a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic toxin (dnt) gene, and a heterologous ampG gene replacing the Bordetella ampG gene;
- mixing the live attenuated Bordetella strain with a pharmaceutically acceptable carrier to yield a vaccine mixture;
- and
- separating the vaccine mixture into single doses.
Dependencies are inferred from the claim text.